A key official in the former Trump administration raised serious concerns with the 340B program during the keynote address at [...] …
Month: October 2024
An influential drug industry expert said that he expects Johnson & Johnson (J&J) to sue the government over its refusal [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A political action committee (PAC) that funded efforts opposing state 340B contract pharmacy access bills through misleading claims linking the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An influential California newspaper recently urged against a November ballot measure, which would require certain healthcare providers in the state [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...] …